Abstract
Aim
The haptoglobin (Hp) 2-2 genotype has been shown to increase the risk of coronary artery disease, kidney dysfunction and mortality from cardiovascular and renal causes in type 1 diabetes (T1D). Similar associations, however, have not been observed in those without diabetes. As cardiac autonomic neuropathy (CAN) is a cardiovascular disease risk factor, we assessed the presence of an association between the Hp 2-2 genotype and CAN.
Methods
The study included 216 individuals with childhood-onset T1D and 200 individuals with normal glucose tolerance (NGT) of similar age and gender distribution to their counterparts with T1D. CAN was assessed using an electrocardiogram as an abnormal, age-specific, heart rate response to deep breathing. Multivariable logistic regression models were used to assess the association between the Hp 2-2 genotype and CAN.
Results
Compared with NGT, participants with T1D had a similar proportion of Hp 2-2 carriers (41.5% vs. 32.0%, p = 0.05) but a greater CAN prevalence (28.2% vs. 5.0%, p < 0.0001). In multivariable logistic regression models, those carrying the Hp 2-2 genotype had significantly higher odds of CAN compared with Hp 1-1 or Hp 2-1 carriers (OR = 2.27, p = 0.01). The presence of T1D (OR = 4.20, p = 0.0003), hypertension (OR = 2.08, p = 0.03), eGFR (OR = 0.98, p = 0.01) and WBC count (OR = 1.21, p = 0.02) were also associated with CAN. There was no T1D by Hp interaction (p = 0.92), although in stratified analyses, the Hp–CAN association was significant only in T1D.
Conclusions
The Hp 2-2 genotype was independently associated with greater odds of CAN in T1D though no definitive conclusions could be made in NGT.
Similar content being viewed by others
References
Langlois MR, Delanghe JR (1996) Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42(10):1589–1600
Costacou T, Ferrell RE, Orchard TJ (2008) Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 57(6):1702–1706
Costacou T, Evans RW, Orchard TJ (2016) Glycaemic control modifies the haptoglobin 2 allele-conferred susceptibility to coronary artery disease in type 1 diabetes. Diabet Med 33(11):1524–1527
Orchard TJ, Backlund JC, Costacou T et al (2016) Haptoglobin 2-2 genotype and the risk of coronary artery disease in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study (DCCT/EDIC). J Diabetes Complic 30(8):1577–1584
Costacou T, Ferrell RE, Ellis D et al (2009) Haptoglobin genotype and renal function decline in type 1 diabetes. Diabetes 58(12):2904–2909
Orchard TJ, Sun W, Cleary PA et al (2013) Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes 62(9):3218–3223
Costacou T, Orchard TJ, Moon CH et al (2018) Is magnetic resonance imaging detection of kidney iron deposition increased in haptoglobin 2-2 genotype carriers with type 1 diabetes? Antioxid Redox Signal 29(8):735–741
Costacou T, Orchard TJ (2016) The Haptoglobin genotype predicts cardio-renal mortality in type 1 diabetes. J Diabetes Complications 30(2):221–226
Pop-Busui R, Boulton AJ, Feldman EL et al (2017) Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care 40(1):136–154
Boulton AJ, Vinik AI, Arezzo JC et al (2005) Diabetic neuropathies: a statement by the american diabetes association. Diabetes Care 28(4):956–962
Vinik AI, Maser RE, Mitchell BD et al (2003) Diabetic autonomic neuropathy. Diabetes Care 26(5):1553–1579
Spallone V, Ziegler D, Freeman R et al (2011) Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 27(7):639–653
Christensen MMB, Hommel EE, Jorgensen ME et al (2018) Prevalence of diabetic neuropathy in young adults with type 1 diabetes and the association with insulin pump therapy. Diabetes Technol Ther 1:1–2. https://doi.org/10.1089/dia.2018.0249
Jaiswal M, Divers J, Urbina EM et al (2018) Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the search for diabetes in youth cohort study. Pediatr Diabetes 19(4):680–689
Hansen CS, Theilade S, Lajer M et al (2018) Cardiovascular autonomic neuropathy and bone metabolism in type 1 diabetes. Diabet Med 35(11):1596–1604
Pop-Busui R, Low PA, Waberski BH et al (2009) Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the diabetes control and complications trial/epidemiology of diabetes interventions and complications study (DCCT/EDIC). Circulation 119(22):2886–2893
Stella P, Ellis D, Maser RE et al (2000) Cardiovascular autonomic neuropathy (expiration and inspiration ratio) in type 1 diabetes. Incidence and predictors. J Diabetes Complic 14(1):1–6
Maser RE, Mitchell BD, Vinik AI et al (2003) The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 26(6):1895–1901
Pop-Busui R, Braffett BH, Zinman B et al (2017) Cardiovascular autonomic neuropathy and cardiovascular outcomes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Care 40(1):94–100
Christensen JH, Krarup HB, Riahi S et al (2005) Heart rate variability is associated with haptoglobin phenotype in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil 12(3):221–225
Strandhave C, Svensson M, Krarup H et al (2013) Haptoglobin genotype and risk markers of cardiovascular disease in patients with chronic kidney disease. Int J Nephrol 2013:650847
Orchard TJ, Dorman JS, Maser RE et al (1990) Factors associated with avoidance of severe complications after 25 yr of IDDM Pittsburgh epidemiology of diabetes complications study I. Diabetes Care 13(7):741–747
Ellis D, Buffone GJ (1977) New approach to evaluation of proteinuric states. Clin Chem 23(4):666–670
Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Int Med 150(9):604–612
Koch W, Latz W, Eichinger M et al (2002) Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 48(9):1377–1382
Costacou T, Evans RW, Orchard TJ (2015) Does the concentration of oxidative and inflammatory biomarkers differ by haptoglobin genotype in type 1 diabetes? Antioxid Redox Signal 23(18):1439–1444
Cahill LE, Levy AP, Chiuve SE et al (2013) Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol 61(7):728–737
Levy AP, Hochberg I, Jablonski K et al (2002) Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. J Am Coll Cardiol 40(11):1984–1990
Roguin A, Koch W, Kastrati A et al (2003) Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care 26(9):2628–2631
Dimova R, Tankova T, Guergueltcheva V et al (2017) Risk factors for autonomic and somatic nerve dysfunction in different stages of glucose tolerance. J Diabetes Complic 31(3):537–543
Foss CH, Vestbo E, Froland A et al (2001) Autonomic neuropathy in nondiabetic offspring of type 2 diabetic subjects is associated with urinary albumin excretion rate and 24-h ambulatory blood pressure: the Fredericia Study. Diabetes 50(3):630–636
Acknowledgements
We are indebted to study participants and staff for their invaluable contributions to the EDC and RETRO HDLc studies. This research was supported by the National Institutes of Health Grant HL130153 and DK34818, and by the Rossi Memorial Fund.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical standard
The study was conducted in accordance with the principles of the Declaration of Helsinki as revised in 2008.
Human and animal rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the responsible institutional and national research committee on human experimentation and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Managed by Antonio Secchi.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ju, J., Tomaszewski, E.L., Orchard, T.J. et al. The haptoglobin 2-2 genotype is associated with cardiac autonomic neuropathy in type 1 diabetes: the RETRO HDLc study. Acta Diabetol 57, 271–278 (2020). https://doi.org/10.1007/s00592-019-01422-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-019-01422-6